IRIS
AMODIO, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.727
EU - Europa 674
AS - Asia 146
Continente sconosciuto - Info sul continente non disponibili 16
AF - Africa 7
SA - Sud America 6
OC - Oceania 2
Totale 2.578
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.679
IT - Italia 305
SE - Svezia 189
CN - Cina 94
GB - Regno Unito 88
CA - Canada 48
RO - Romania 26
IN - India 21
DE - Germania 18
EU - Europa 15
IR - Iran 9
RU - Federazione Russa 9
JP - Giappone 8
UA - Ucraina 7
EG - Egitto 6
NL - Olanda 6
FR - Francia 5
GR - Grecia 5
CH - Svizzera 4
CL - Cile 4
AT - Austria 3
ES - Italia 3
MY - Malesia 3
AU - Australia 2
BD - Bangladesh 2
DK - Danimarca 2
PK - Pakistan 2
TR - Turchia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BR - Brasile 1
FI - Finlandia 1
IL - Israele 1
NO - Norvegia 1
PH - Filippine 1
PL - Polonia 1
PT - Portogallo 1
SG - Singapore 1
TW - Taiwan 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 2.578
Salva come PNG Salva come JPEG
Città #
Chandler 388
Lawrence 189
Princeton 189
Catanzaro 132
Wilmington 106
London 82
Chicago 73
Beijing 66
Des Moines 57
Ashburn 48
Ottawa 45
Redwood City 20
Horia 14
Norwalk 13
Pune 12
Rome 11
Hanover 10
Redmond 10
Timisoara 10
Cosenza 9
Bari 8
Naples 8
Ann Arbor 7
San Jose 7
Settingiano 7
Hefei 6
Reggio Calabria 6
West Jordan 6
Andover 5
Augusta 5
Boardman 4
Caserta 4
Hebei 4
Lamezia Terme 4
New York 4
Novokuznetsk 4
Ahmedabad 3
Cetraro 3
Fayetteville 3
Masera 3
Nanjing 3
Napoli 3
San Mateo 3
Treviso 3
Zhengzhou 3
Apo 2
Aversa 2
Brugnera 2
Cairo 2
Ceglie Del Campo 2
Diemen 2
Fiumicino 2
Fuzhou 2
Grottaglie 2
Guangzhou 2
Islamabad 2
Leawood 2
Milan 2
Mountain View 2
Portici 2
Shenyang 2
Sistan 2
Spezzano della Sila 2
Stalettì 2
Taranto 2
Toronto 2
Trapani 2
Vienna 2
Vigliano Biellese 2
Alexandria 1
Baotou 1
Batu Caves 1
Bocale 1
Brinklow 1
Chemnitz 1
Chengdu 1
Clearwater 1
Crotone 1
Cupertino 1
Decollatura 1
Dhaka 1
Esslingen am Neckar 1
Fairfield 1
Ferrara 1
Filadelfia 1
Frankfurt am Main 1
Giugliano in Campania 1
Groningen 1
Haifa 1
Helsinki 1
Izmir 1
Jinhua 1
Kaohsiung 1
Kuala Lumpur 1
Los Angeles 1
Madrid 1
Manila 1
Melbourne 1
Messina 1
Montevideo 1
Totale 1.679
Salva come PNG Salva come JPEG
Nome #
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 51
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 48
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 42
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 42
TARGETING OF DEREGULATED LNCRNA NEAT1 AFFECTS MULTIPLE MYELOMA ACTIVITY 39
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 39
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 36
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 34
Early hematopoietic zinc finger protein, a novel transcription co-factor with a potential role in haematopoietic homeostasis and leukaemogenesis 33
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 33
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer 32
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 32
P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS 32
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 30
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 30
IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy 30
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells 30
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 29
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 29
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 29
Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma 28
Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction 28
Early Hematopoietic Zinc Finger protein (EHZF), the human homologue to Evi3, is highly expressed in primitive human hematopoietic cells 27
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats 27
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 27
In Vitro Silencing of lncRNAs Using LNA GapmeRs 27
Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches 26
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 26
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 25
A 13 mer LNA miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 25
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 24
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 23
In vitro expansion of tumour cells derived from blood and tumour tissue is useful to redefine personalized treatment in non-small cell lung cancer patients 23
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 23
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network 23
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 22
Early hematopoietic zinc finger protein - zinc finger protein 521 (EHZF/ZNF521): a candidate regulator of diverse immature cells 22
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. 22
miR-22 suppresses DNA ligase III addiction in multiple myeloma 22
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 21
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 21
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 21
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 20
Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment 20
In vitro and vivo activity against multiple myeloma cells of a novel locked nucleic acid (LNA)-miR-221 inhibitor 20
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 20
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 20
Contribution of PKB/AKT signaling to thyroid cancer 20
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 19
Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma 19
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma 19
Biological Insights into Myeloma and Other B Cell Malignancies 19
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 19
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 18
Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients 18
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 18
Early Hematopoietic Zinc Finger (EHZF/ZNF521) prevents tumor cell recognition by Natural Killer Cells 18
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 18
Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells 18
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells 17
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 17
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 16
Functional Analysis of microRNA in Multiple Myeloma 16
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma 16
Activating E17K mutation in the gene encoding the protein kinase B/AKT in squamous cell carcinoma of the lung 16
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 16
Chromofungin, CgA47-66-derived peptide, produces basal cardiac effects and postconditioning cardioprotective action during ischemia/reperfusion injury 16
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. 15
Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors 15
Early Hematopoietic Zinc Finger protein (EHZF), a novel co-transcription factor: functional properties, expression in myelogenous leukaemias and interactions with histone deacetylases 15
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. 15
Znf521 enhances mll‐af9‐dependent hematopoietic stem cell transformation in acute myeloid leukemias by altering the gene expression landscape† 15
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 14
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 14
Challenges in multiple myeloma chemoprevention: potential role of natural, synthetic and endogenous molecules 14
Radiation induced by-stander effect: possible RNA implication in DNA damage transmission? 14
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. 13
Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs 13
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 13
The non-coding RNA landscape of plasma cell dyscrasias 13
Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells 13
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 13
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma 12
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 12
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth 12
Cytoskeleton Regulator PAK4 plays a role in growth and survival of Myeloma with a potential therapeutic intervention using PAK4 Allosteric Modulators (PAMs) 12
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 12
The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma 12
Current status and future perspectives on therapeutic potential of apigenin: Focus on metabolic-syndrome-dependent organ dysfunction 12
Non-Coding RNA-Dependent Regulation of Mitochondrial Dynamics in Cancer Pathophysiology 11
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 11
Early hematopoietic zinc finger (EHZF), a multifunctional transcription co-factor expressed in human early hematopoietic cells and AML blasts 11
Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma 11
The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1 11
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 11
Genomic instability in multiple myeloma: A “non‐coding rna” perspective 11
Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. 10
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 10
Mir-23b Plays a Critical Role As a Tumor Suppressor miRNA In Multiple Myeloma 10
Histone Deacetylase Inhibitors Show Antiepileptogenic and Antidepressant Effects in the WAG/Rij Rat Model of Absence Epilepsy 10
Totale 2.096
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.106
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.106
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020243 0 0 0 15 133 7 5 4 5 11 13 50
2020/2021337 19 3 14 14 34 21 20 14 54 45 72 27
2021/2022569 23 2 5 154 38 13 24 113 54 61 71 11
2022/20231.183 386 64 71 68 100 93 5 87 163 51 70 25
2023/2024454 113 73 34 42 28 129 13 8 2 12 0 0
Totale 2.786